Drug Profile
Triamcinolone controlled-release - EyePoint Pharmaceuticals
Alternative Names: IBI-20089Latest Information Update: 05 Nov 2021
Price :
$50
*
At a glance
- Originator Icon Bioscience
- Developer EyePoint Pharmaceuticals; Icon Bioscience
- Class Analgesics; Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Pregnadienes; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Age-related macular degeneration; Diabetic macular oedema; Retinal oedema
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for phase-I development in Diabetic-macular-oedema in USA (Intravitreous, Injection)
- 28 Mar 2018 Icon Bioscience has been acquired by EyePoint Pharmaceuticals
- 03 May 2016 Phase-I clinical trials in Diabetic macular oedema in USA (Intravitreous)